Diverse stage-dependent effects of glucocorticoids in a murine model of viral myocarditis

Hiroshi Nakamura1, Ichiro Kunitsugu, Keiichi Fukuda

  • 1Department of Community Health and Medicine, Yamaguchi University Graduate School of Medicine, Ube, Japan. nahirosi@yamaguchi-u.ac.jp

Journal of Cardiology
|February 19, 2013
PubMed
Abstract

Insights

Early dexamethasone (DEX) treatment improves survival in viral myocarditis. Late DEX is harmful and its benefits are blocked by COX-2 inhibitors, suggesting a direct effect on heart cells.

Area of Science:

  • Cardiology
  • Virology
  • Immunology

Background:

  • The role of glucocorticoids in viral myocarditis remains debated.
  • Acute viral myocarditis, often caused by Coxsackie B3 virus (CVB3), presents a significant clinical challenge.

Purpose of the Study:

  • To investigate the therapeutic window for glucocorticoid (dexamethasone) treatment in a mouse model of acute viral myocarditis.
  • To elucidate the mechanisms underlying the effects of dexamethasone on viral myocarditis progression.

Main Methods:

  • A/J mice were infected with CVB3 and treated with dexamethasone (DEX) at different time points: pre-infection, immediately post-infection, or 7 days post-infection.
  • Survival rates, cardiac function, fibrosis, immune cell infiltration, and viral titers were assessed.
  • The role of cyclooxygenase-2 (COX-2) was evaluated using a selective COX-2 inhibitor (NS-398).

Main Results:

  • Early DEX administration (pre- or immediately post-infection) improved survival, attenuated cardiac dysfunction, and reduced inflammation and fibrosis.
  • Late DEX administration (starting day 7 post-infection) decreased survival and increased pro-inflammatory cytokine levels (TNF-α, IFN-γ).
  • The beneficial effects of early DEX were abolished by co-administration of a COX-2 inhibitor, which also increased viral titers.

Conclusions:

  • Early dexamethasone treatment is beneficial in acute viral myocarditis, while late treatment is detrimental.
  • The protective effects of early DEX are mediated, at least in part, through COX-2 inhibition.
  • Dexamethasone may exert direct protective effects on cardiomyocytes, independent of its anti-inflammatory actions on immune cells.

Related Concept Videos

Myocarditis I: Introduction01:21

Myocarditis I: Introduction

Myocarditis is inflammation of the myocardium, which is the muscular layer of the heart.EtiologyMyocarditis has a diverse etiology, including a wide range of infectious and non-infectious causes:Infectious CausesViral: Common viruses include Coxsackie A and B, adenovirus, parvovirus B19, enteroviruses, and influenza A.Bacterial: Examples include infections caused by Streptococcus, Staphylococcus, and Mycoplasma species.Rickettsial: Infections like Rocky Mountain spotted fever can result in...
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
Myocarditis II: Clinical Features and Diagnostic Tests01:27

Myocarditis II: Clinical Features and Diagnostic Tests

Myocarditis is an inflammation of the heart muscle. The symptoms vary widely, encompassing asymptomatic presentations to severe, acute manifestations.Clinical PresentationAsymptomatic cases: In some instances, myocarditis may be asymptomatic, with the infection resolving without intervention. These cases often go undetected unless discovered incidentally through diagnostic imaging or tests conducted for other reasons.General Early Symptoms: Early symptoms of myocarditis are non-specific and can...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...